Skip to main content
  • Saved

made a Post

Addition of Nivolumab to Neoadjuvant Chemotherapy in Resectable Stage IIIA NSCLC

Source :

In the Spanish phase II NADIM trial reported in The Lancet Oncology , Provencio et al found that the addition of nivolumab to neoadjuvant chemotherapy and the use of adjuvant nivolumab were associated with high 24-month rates of progression-free survival in patients with resectable stage IIIA non-small cell lung cancer (NSCLC).